Guy Sauvageau is a Principal Investigator in the Molecular Genetics of Stem Cells research unit at the Institute for Research in Immunology and Cancer (IRIC) and a Professor in the Department of Medicine, Faculty of Medicine at Université de Montréal. He is the Canada Research Chair in Molecular of Normal and Leukemia Stem Cells. In 2014, Dr. Sauvageau was named Radio-Canada’s Scientist of the Year and La Presse’s Personality of the Year in the Science Category for his discovery of UM171. He was the founding scientific director (2003-2014) of IRIC at University of Montreal and CEO from 2007-2015.
Mr. Millette combines a solid background in finance and law, having practised in the areas of accounting, finance and management consulting with a leading firm of chartered professional accountants for several years, and in the areas of corporate and securities law, financings and business acquisitions and sales for over a decade, including several years as a partner, with a top tier international law firm. He has a broad range of financial, legal and strategic experience across several industries, including pharmaceuticals, life sciences and healthcare. Mr. Millette is a lawyer, holds a bachelor of commerce and a law degree from the University of Montreal, and holds the designations of Chartered Professional Accountant (CPA, CA) and Chartered Financial Analyst (CFA).
Anne Marinier is currently Director of Medicinal Chemistry at IRIC and Associate Professor in the Department of Chemistry at the Université de Montreal. She leads a team of 40 scientists and is in charge of developing a portfolio of several drug discovery projects at IRIC. She brings close to 25 years of experience in medicinal chemistry and a strong industry expertise in all aspects of drug discovery with numerous successes including the advancement of a small molecule in Phase II clinical studies in collaboration with Bristol-Myers Squibb, and the development of UM171.
Peter Zandstra is the Chief Scientific Officer at CCRM and Founding Director, School of Biomedical Engineering at the University of British Columbia. He is also the Director of UBC’s Michael Smith Laboratories and is the Canada Research Chair in Stem Cell Bioengineering.
Pierre Caudrelier obtained his degree in medicine from University of Paris and holds a degree in applied epidemiology and biostatistics from the Universities of Tours and Bordeaux. During the past 30 years, he has held various senior and management positions and has acquired sound R&D expertise with major pharmaceutical and biopharmaceutical companies in the fields of immunology, transplantation, cell therapy and oncology. Before joining ExCellThera, he successively held the positions of clinical program director of Sanofi Pasteur, Vice President, Scientific and Medical Affairs of I.D.M. Biotech, Vice President, Clinical and Medical Affairs of Celmed BioSciences – Kiadis Pharma, and General Manager of its North-American subsidiary, and Chief Medical Officer of Theratechnologies.
Michael May is currently the Chief Executive Officer of CCRM. Prior to CCRM, Michael was the President, Chief Operating Officer and co-founder of Rimon Therapeutics Ltd., a Toronto-based regenerative medicine company developing novel medical polymers that possess drug-like activity. Michael sits on a number of Boards and advisory committees, including: MaRS Innovation, Rimon Therapeutics Ltd., 20/20 Vision, the Advanced Regenerative Tissue Engineering Centre, the Department of Chemical Engineering and Applied Chemistry, at the University of Toronto and the McMaster Mohawk Biotechnology Program.
Nadine Beauger is Chief Executive Officer at the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) at the University of Montreal. Before this appointment, Dr. Beauger was Vice-President – Scientific Liaison (intellectual property, academia-industry relations) at the same organization that she joined in 2009. She was instrumental at building IRICoR’s project portfolio and related intellectual property (IP) activities. She led strategic IP portfolio management including a dedicated IP budget, building and implementing the strategy for a portfolio of patent families (40) which have led to successful licensing agreements and partnerships with industry.